Semaglutide

GLP-1 receptor agonist · Antidiabetic · Anti-obesity · Cardiovascular risk reduction agent

Semaglutide

Ozempic (T2DM SC), Wegovy (obesity SC), Rybelsus (oral T2DM)

Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk, marketed as Ozempic (weekly subcutaneous, for type 2 diabetes mellitus), Wegovy (weekly subcutaneous, for obesity, cardiovascular risk reduction in obesity without diabetes, and MASH with fibrosis), and Rybelsus (daily oral tablet, for T2DM). It is, by revenue, the highest-grossing medicine on the planet as of 2024. Semaglutide is the second weekly GLP-1 RA from Novo Nordisk's incretin program (after liraglutide) and the molecule that, more than any other, made obesity treatment a mainstream rather than a specialty intervention.

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

<indication ref="diabetes-type-2" author="MDElliottMD"/> <indication ref="obesity" author="MDElliottMD"/> <indication ref="cv-risk-obesity" author="MDElliottMD"/> <indication ref="mash-fibrosis" author="MDElliottMD"/> <indication ref="ckd-t2dm" author="MDElliottMD"/>

+ Add a problem

Titration strategies

Ozempic — standard T2DM titration▲0▼×

0.25 mg SC weekly × 4 weeks (non-therapeutic; tolerance ramp only)

→ 0.5 mg SC weekly × ≥4 weeks → 1 mg SC weekly × ≥4 weeks if further glycemic control needed → 2 mg SC weekly (max) if needed

Slower titration is reasonable in any patient with significant GI symptoms — holding at a tolerated dose for 8–12 weeks before advancing is standard practice.

Wegovy — standard obesity titration▲0▼×

0.25 mg SC weekly × 4 weeks

→ 0.5 mg × 4 weeks → 1 mg × 4 weeks → 1.7 mg × 4 weeks → 2.4 mg weekly (maintenance)

If a dose escalation is not tolerated, hold at the prior dose for an extra 4 weeks before advancing. Discontinue if patient cannot tolerate 1.7 mg after extended titration.

Rybelsus — standard oral T2DM titration▲0▼×

3 mg PO daily × 30 days (non-therapeutic ramp)

→ 7 mg PO daily × ≥30 days → 14 mg PO daily (max)

Critical patient instruction: swallow whole, with no more than 120 mL (4 oz) of plain water, on an empty stomach, ≥30 minutes before the first food, drink, or any other oral medicine of the day.

+ Add a titration strategy

Effects

Subjective effects vary considerably with dose and titration speed but reliably include:

• Early satiety — meals feel "complete" at a fraction of prior intake
• Food noise quieting — the most commonly volunteered subjective change. Patients report that intrusive food-related thoughts simply stop.
• Reduced alcohol craving — corroborated by observational and small RCT data; mechanism likely shared with food reward circuitry
• Nausea — dose-dependent, worst in first 1–2 weeks of any new dose level
• Constipation or diarrhea (variable, can alternate)
• Sulfurous eructation (a small but very real subgroup)
• Reduced taste preference for fatty / sweet foods in many users

+ Add an effect

Pharmacokinetics

Acylation with a C18 fatty diacid drives non-covalent binding to serum albumin, slowing renal clearance and DPP-4 access. The Aib8 substitution renders the peptide DPP-4-resistant. Resulting terminal half-life ~165 h means once-weekly subcutaneous dosing produces near-steady-state plasma levels.

Oral semaglutide (Rybelsus) is co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently raises gastric pH and protects the peptide locally — yielding ~0.4–1% bioavailability, which is enough at 14 mg daily to match Ozempic 0.5 mg weekly for glycemic effect (but not for weight loss). Strict fasting administration is mandatory; any concurrent food or beverage destroys absorption.

Predominantly catabolic clearance via proteolysis; renal and hepatic impairment do not require dose adjustment. No CYP-mediated metabolism, so the interaction profile is dominated by gastric emptying effects on other oral medicines, not pharmacokinetic competition.

Pharmacodynamics

At maintenance doses semaglutide produces:

• HbA1c reduction of ~1.5–2.0 percentage points (Ozempic 1 mg)
• Weight loss of ~6 kg (Ozempic 1 mg, T2DM) to ~15% body weight (Wegovy 2.4 mg, obesity without T2DM, STEP-1)
• Systolic BP reduction of ~5 mmHg
• Modest LDL-C reduction, larger triglyceride reduction
• 20% relative risk reduction in MACE in obesity without T2DM (SELECT)
• 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)

  Interactions

No interactions reported yet.

+ Add an interaction

Pregnancy and lactation

Category formerly X-equivalent; current FDA labeling: avoid in pregnancy. Animal embryofetal toxicity is well-documented. Because the half-life is ~1 week, current guidance is to discontinue at least 2 months before any planned conception.

Postpartum: not recommended during breastfeeding pending more data; small molecule transfer to milk is unlikely given peptide structure but not formally characterized.

Importantly: semaglutide is not a contraceptive, and the medicine may restore ovulation in patients with PCOS or obesity-associated anovulation. Patients of childbearing potential should be counseled about contraception before starting.

Monitoring

• Baseline: HbA1c, weight, BP, renal function, lipid panel, ALT/AST (especially for MASH indication)
• Personal or family history of MTC or MEN2 — contraindicated, do not start
• Every 3 months for first year: HbA1c, weight, GI tolerability, signs of pancreatitis or gallbladder disease
• Annual: renal function, lipids
• Pre-procedure: hold weekly dose ≥7 days before any planned anesthesia (per ASA 2024 guidance) due to delayed gastric emptying / aspiration risk

  Patient counseling

• Slow titration is non-negotiable for tolerability. Patients who insist on faster ramps usually quit from GI side effects.
• Inject SC in abdomen, thigh, or upper arm; rotate sites. Pen is single-patient, multi-dose.
• GI side effects almost always peak in first 2–4 weeks of any new dose level, then attenuate.
• Eat smaller portions earlier in the day. Plate sizes will feel comically large after a few weeks — that is the medicine working, not a problem to fix.
• Hydrate aggressively (volume depletion → AKI is a real risk).
• Resistance training during weight loss protects lean mass and is strongly encouraged.
• If a weekly dose is missed: take within 5 days; if >5 days, skip and resume on the next regular day.
• Avoid alcohol during titration weeks (compounds nausea).
• Pregnancy planning: stop ≥2 months before trying to conceive.
• Surgery: tell every anesthesiologist and surgeon you are on a weekly GLP-1 RA. Hold dose 7 days pre-op.

  Relevant anecdote

▲0▼ ▲0▼ ▲0▼ ▲0▼

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

GLP-1 receptor agonist · Tirzepatide · Liraglutide · Dulaglutide · Exenatide · Type 2 diabetes mellitus · Obesity · MASH

References

[[File:31-amino-acid acylated peptide analog of human GLP-1 (7–37), with Aib substitution at position 8 (blocks DPP-4 cleavage) and a C18 fatty diacid linked via γGlu-2×OEG spacer at Lys26 (drives albumin binding → ~165 h half-life)|frameless|240px|alt=Structure of Semaglutide]]

Summary

Classes

GLP-1 receptor agonist · Antidiabetic · Anti-obesity · Cardiovascular risk reduction agent

Common uses

• Cardiovascular risk reduction in obesity★★★★★★★★★★★★★★★—×
• Chronic kidney disease in type 2 diabetes★★★★★★★★★★★★★★★—×
• MASH with stage 2-3 fibrosis★★★★★★★★★★★★★★★—×
• Obesity★★★★★★★★★★★★★★★—×
• Type 2 diabetes mellitus★★★★★★★★★★★★★★★—×

Pharmacy

Starting dose

Ozempic: 0.25 mg SC weekly × 4 wk · Wegovy: 0.25 mg SC weekly × 4 wk · Rybelsus: 3 mg PO daily × 30 d

Preparations

Pre-filled multi-dose pen (0.25 / 0.5 / 1 / 2 mg, Ozempic; 0.25 / 0.5 / 1 / 1.7 / 2.4 mg, Wegovy) · Oral tablet 3 / 7 / 14 mg co-formulated with SNAC absorption enhancer (Rybelsus)

US FDA Max

2 mg/wk SC (Ozempic) · 2.4 mg/wk SC (Wegovy) · 14 mg PO daily (Rybelsus)

Pharmacology

Routes

Subcutaneous (abdomen, thigh, upper arm) · Oral (Rybelsus only, on empty stomach with ≤120 mL water, ≥30 min before any food/drink/other oral medicine)

Onset

Glycemic effect within days; full weight effect over months

Duration

~7 days (weekly SC dosing) · ~24 h (oral)

Half-life

~165 hours (~1 week) — among the longest of any GLP-1 RA

Bioavailability

SC ~89% · Oral ~0.4–1% (SNAC-enhanced)

Pregnancy

Avoid. Discontinue ≥2 months before planned pregnancy due to long half-life. Animal data show embryofetal harm. Not contraceptive — but rapid weight loss + improved ovulation may unmask fertility in PCOS.

Legal status

Rx-only · Schedule: none (not a controlled substance)

Purported mechanism

Selective long-acting agonist of the GLP-1 receptor (class B GPCR). Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and direct cardiovascular and renal protective effects.